keyword
MENU ▼
Read by QxMD icon Read
search

cetuximab AND radiotherapy

keyword
https://www.readbyqxmd.com/read/28808428/a-comparison-of-concurrent-cisplatin-versus-cetuximab-with-radiotherapy-in-locally-advanced-head-and-neck-cancer-a-bi-institutional-analysis
#1
William A Stokes, Whitney A Sumner, Kiersten L Breggren, John T Rathbun, David Raben, Jessica D McDermott, Gregory Gan, Sana D Karam
AIM: To present our experience comparing cisplatin- and cetuximab-based radiotherapy for locally-advanced head and neck squamous cell carcinoma. BACKGROUND: The comparative effectiveness of cisplatin-based chemoradiotherapy (CRT) versus cetuximab-based bioradiotherapy (BRT) for locally-advanced head and neck squamous cell carcinoma (LAHNSCC) continues to be explored. MATERIALS AND METHODS: Outcomes of LAHNSCC patients treated with CRT (125) or BRT (34) at two institutions were compared retrospectively, with attention to overall survival (OS), cancer-specific survival (CSS), locoregional control (LRC), and distant control (DC)...
September 2017: Reports of Practical Oncology and Radiotherapy
https://www.readbyqxmd.com/read/28807520/egfr-amplification-plus-gene-expression-profiling-predicts-response-to-combined-radiotherapy-with-egfr-inhibition-a-preclinical-trial-in-10-hnscc-tumour-xenograft-models
#2
Lydia Koi, Steffen Löck, Annett Linge, Cedric Thurow, Sandra Hering, Michael Baumann, Mechthild Krause, Kristin Gurtner
BACKGROUND AND PURPOSE: Improvement of the results of radiotherapy by EGFR inhibitors is modest, suggesting significant intertumoural heterogeneity of response. To identify potential biomarkers, a preclinical trial was performed on ten different human squamous cell carcinoma xenografts of the head and neck (HNSCC) studying in vivo and ex vivo the effect of fractionated irradiation and EGFR inhibition. Local tumour control and tumour growth delay were correlated with potential biomarkers, e...
August 11, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28753113/a-potential-therapy-for-chordoma-via-antibody-dependent-cell-mediated-cytotoxicity-employing-nk-or-high-affinity-nk-cells-in-combination-with-cetuximab
#3
Rika Fujii, Jeffrey Schlom, James W Hodge
OBJECTIVE Chordoma is a rare bone tumor derived from the notochord and is resistant to conventional therapies such as chemotherapy, radiotherapy, and targeting therapeutics. Expression of epidermal growth factor receptor (EGFR) in a large proportion of chordoma specimens indicates a potential target for therapeutic intervention. In this study the authors investigated the potential role of the anti-EGFR antibody cetuximab in immunotherapy for chordoma. METHODS Since cetuximab is a monoclonal antibody of the IgG1 isotype, it has the potential to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) employing natural killer (NK) cells as effectors...
July 28, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28740554/concurrent-chemoradiotherapy-with-or-without-anti-egfr-targeted-treatment-for-stage-ii-ivb-nasopharyngeal-carcinoma-retrospective-analysis-with-a-large-cohort-and-long-follow-up
#4
Rui You, Yi-Jun Hua, You-Ping Liu, Qi Yang, Yi-Nuan Zhang, Ji-Bin Li, Chao-Feng Li, Xiong Zou, Tao Yu, Jing-Yu Cao, Meng-Xia Zhang, Rou Jiang, Rui Sun, Hao-Yuan Mo, Ling Guo, Ka-Jia Cao, Ai-Hua Lin, Ying Sun, Chao-Nan Qian, Jun Ma, Ming-Yuan Chen
We examined the benefits of the combination of anti-EGFR targeted treatment, cetuximab (CTX) or nimotuzumab (NTZ) and concurrent platinum-based chemoradiotherapy (CCRT) compared with CCRT alone in patients with stage II - IVb nasopharyngeal carcinoma (NPC). A total of 1,628 eligible patients with stage II - IVb NPC, who received CCRT (three cycles of 100 mg/m(2) cisplatin every 3 weeks with intensity-modulated radiotherapy) with or without CTX or NTZ between June 2009 and December 2013 were included in the analysis...
2017: Theranostics
https://www.readbyqxmd.com/read/28685354/a-multicenter-phase-2-study-on-the-feasibility-and-efficacy-of-neoadjuvant-chemotherapy-without-radiotherapy-for-locally-advanced-rectal-cancer
#5
Suguru Hasegawa, Saori Goto, Takuya Matsumoto, Koya Hida, Kenji Kawada, Ryo Matsusue, Takashi Yamaguchi, Ryuta Nishitai, Dai Manaka, Shigeru Kato, Yoshio Kadokawa, Satoshi Yamanokuchi, Junichiro Kawamura, Masazumi Zaima, Takahisa Kyogoku, Akiyoshi Kanazawa, Yukiko Mori, Masashi Kanai, Shigemi Matsumoto, Yoshiharu Sakai
BACKGROUND: This prospective multicenter phase 2 study aimed to evaluate the feasibility and efficacy of neoadjuvant chemotherapy (NAC) without radiotherapy for locally advanced rectal cancer (LARC). METHODS: Patients with LARC (cStage II and III) were included in the study. Those with cT4b tumor were excluded. Six cycles of modified FOLFOX6 (mFOLFOX6) plus either bevacizumab or cetuximab, depending on KRAS status, were administered before surgery. The primary end point of the study was the R0 resection rate...
July 6, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28598813/identification-of-a-novel-atm-inhibitor-with-cancer-cell-specific-radiosensitization-activity
#6
Amy J C Dohmen, Xiaohang Qiao, Anja Duursma, Ruud H Wijdeven, Cor Lieftink, Floor Hageman, Ben Morris, Pasi Halonen, Conchita Vens, Michiel W M van den Brekel, Huib Ovaa, Jacques Neefjes, Charlotte L Zuur
Treatment of advanced head and neck squamous cell carcinoma (HNSCC) is plagued by low survival and high recurrence rates, despite multimodal therapies. Presently, cisplatin or cetuximab is used in combination with radiotherapy which has resulted in minor survival benefits but increased severe toxicities relative to RT alone. This underscores the urgent need for improved tumor-specific radiosensitizers for better control with lower toxicities. In a small molecule screen targeting kinases, performed on three HNSCC cell lines, we identified GSK635416A as a novel radiosensitizer...
May 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28597041/efficacy-and-safety-of-postoperative-bio-chemoradiotherapy-using-cetuximab-and-docetaxel-for-high-risk-head-and-neck-cancer-patients-in-japan
#7
Goshi Nishimura, Osamu Shiono, Daisuke Sano, Kenichiro Yabuki, Yasuhiro Arai, Yoshihiro Chiba, Teruhiko Tanabe, Nobuhiko Oridate
PURPOSE: To confirm the efficacy and safety of cetuximab and docetaxel in postoperative radiotherapy for high-risk head and neck cancer patients who cannot to be administered high-dose cisplatin. PATIENTS AND METHODS: The eligibility criteria required stage III-IVB head and neck cancer patients who had undergone total resection, and for whom pathological evaluation revealed positive or close margins in the primary site and/or extracapsular nodal extension and/or two or more nodal metastases...
July 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28580506/prolonged-overall-treatment-time-and-lack-of-skin-rash-negatively-impact-overall-survival-in-locally-advanced-head-and-neck-cancer-patients-treated-with-radiotherapy-and-concomitant-cetuximab
#8
Julien Roman, Gurvan Dissaux, Maelenn Gouillou, Yves Gobel, Gael Potard, Jean-Christophe Leclere, Virginie Conan-Charlet, Dorothy Gujral, Ronan Abgral, Briac Guibourg, Olivier Pradier, Ulrike Schick
BACKGROUND: Cetuximab, a chimeric monoclonal antibody against EGFR sensitizes tumors to radiotherapy (RT), but is associated with skin and mucosal toxicity. OBJECTIVE: We report outcomes and tolerance of definitive RT in association with cetuximab in patients with locally advanced squamous cell carcinoma (LASCC) of the head and neck. PATIENTS AND METHODS: Between 2006 and 2011, 92 consecutive patients with LASCC of the head and neck were treated with RT and concomitant weekly cetuximab...
August 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28577306/cetuximab-or-nimotuzumab-plus-intensity-modulated-radiotherapy-versus-cisplatin-plus-intensity-modulated-radiotherapy-for-stage-ii-ivb-nasopharyngeal-carcinoma
#9
Rui You, Rui Sun, Yi-Jun Hua, Chao-Feng Li, Ji-Bin Li, Xiong Zou, Qi Yang, You-Ping Liu, Yi-Nuan Zhang, Tao Yu, Jing-Yu Cao, Meng-Xia Zhang, Rou Jiang, Hao-Yuan Mo, Ling Guo, Ka-Jia Cao, Ai-Hua Lin, Chao-Nan Qian, Ying Sun, Jun Ma, Ming-Yuan Chen
To compare intensity-modulated radiotherapy (IMRT) with cisplatin (CDDP) versus cetuximab (CTX) and nimotuzumab (NTZ) for Stage II-IVb Nasopharyngeal Carcinoma (NPC). A total of 1,837 patients with stage II-IVb NPC who received IMRT plus CTX or NTZ, or CDDP between January 2009 and December 2013 were included in the current analysis. Using propensity scores to adjust for potential prognostic factors, a well-balanced cohort of 715 patients was created by matching each patient who underwent IMRT plus concomitant NTZ/CTX with four patients who underwent IMRT plus concomitant CDDP (1:4)...
June 2, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28557105/major-response-to-pembrolizumab-in-two-patients-with-locally-advanced-cutaneous-squamous-cell-carcinoma
#10
E Degache, J Crochet, N Simon, M Tardieu, S Trabelsi, M Moncourier, I Templier, L Foroni, A Lemoigne, N Pinel, H Gil, L Bouillet, M T Leccia, J Charles
Cutaneous squamous cell carcinomas (CSCC) are one of the most frequent types of cancer, with rising incidence rates(1). While the majority are cured with surgery, some CSCC are associated with significant morbidity and mortality due to their local extension and metastatic potential. The recommended treatment for these advanced stages includes radiotherapy, conventional chemotherapy, or cetuximab, which tends to yield modest responses and a high prevalence of toxic effects(2). Anti- Programmed Death-1 (PD-1) therapies recently showed their efficacy in several types of tumour, especially in patients with recurrent or metastatic head and neck squamous cell carcinomas that has continued to progress despite standard-of-care treatment, suggesting the potentical efficacy of anti-PD1 in CSCC (3,4)...
May 30, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28535302/inhibition-of-n-acetylglucosaminyltransferase-v-enhances-the-cetuximab-induced-radiosensitivity-of-nasopharyngeal-carcinoma-cells-likely-through-egfr-n-glycan-alterations
#11
Xiaomin Huang, Ting Liu, Qiongyao Wang, Weiliang Zhu, Hui Meng, Linlang Guo, Ting Wei, Jian Zhang
N-acetylglucosaminyltransferase V (GnT-V), an enzyme that catalyses the formation of the N-linked β-1-6 branching of oligosaccharides, is related to the radiosensitivity of nasopharyngeal carcinoma (NPC). Cetuximab (C225) is an epidermal growth factor receptor (EGFR) inhibitor used as a radiosensitizer in the treatment of NPC. In this study, we used GnT-V as a molecular target to further sensitize cetuximab-treated NPC cells to radiation. The results from two NPC cell lines (CNE1 and CNE2) revealed that the silencing of GnT-V enhanced cetuximab-induced radiosensitivity by decreasing the β-1-6 branching of oligosaccharides on the EGFR...
May 23, 2017: Glycobiology
https://www.readbyqxmd.com/read/28500491/hyperfractionated-accelerated-radiation-therapy-plus-cetuximab-plus-cisplatin-chemotherapy-in-locally-advanced-inoperable-squamous-cell-carcinoma-of-the-head-and-neck-final-5%C3%A2-year-results-of-a-phase%C3%A2-ii-study
#12
Thomas Kuhnt, Andreas Schreiber, Anett Pirnasch, Matthias G Hautmann, Peter Hass, Frank P Sieker, Rita Engenhart-Cabillic, Michael Richter, Kathrin Dellas, Jürgen Dunst
BACKGROUND: Cetuximab (CET) is a potent inhibitor of the epidermal growth factor receptor and has been shown to have activity in squamous cell carcinoma of the head and neck (SCCHN). We conducted a single-arm phase II trial of a combination therapy comprising cisplatin (CIS), CET and hyperfractionated accelerated radiotherapy (HART). PATIENTS AND METHODS: Patients with UICC stage III or IVA/B, M0 SCCHN were enrolled and treated with an initial dose of CET (400 mg/m(2)) and then with a weekly dosage of 250 mg/m(2) during HART...
May 12, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28453615/do-patient-access-schemes-for-high-cost-cancer-drugs-deliver-value-to-society-lessons-from-the-nhs-cancer-drugs-fund
#13
A Aggarwal, T Fojo, C Chamberlain, C Davis, R Sullivan
Background: The NHS Cancer Drugs Fund (CDF) was established in 2010 to reduce delays and improve access to cancer drugs, including those that had been previously appraised but not approved by NICE (National Institute for Health and Care Excellence). After 1.3 billion GBP expenditure, a UK parliamentary review in 2016 rationalized the CDF back into NICE. Methods: This paper analyses the potential value delivered by the CDF according to six value criteria. This includes validated clinical benefits scales, cost-effectiveness criteria as defined by NICE and an assessment of real-world data...
April 27, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28382396/retrospective-evaluation-of-concomitant-cetuximab-and-radiotherapy-tolerance-for-locoregional-advanced-head-and-neck-squamous-cell-carcinoma-treatment-in-patients-unfit-for-platinum-based-chemotherapy
#14
Audrey Rambeau, Radj Gervais, Dominique De Raucourt, Emmanuel Babin, Audrey Emmanuelle Dugué, Carmen Florescu, David Blanchard, Bernard Gery
Radiotherapy associated with cetuximab (Cet-RT) is an alternative treatment to platinum-based chemoradiotherapy in locally advanced head and neck carcinoma (LAHNC). Reviews suggest that the use of cetuximab is associated with poorer tolerance in patients unfit for chemotherapy than in pivotal trial. We retrospectively studied patients first treated by Cet-RT for LAHNC presenting contraindications to chemoradiotherapy. Objectives were treated population description, acute tolerance, progression-free survival (PFS), overall survival (OS), and 3-month clinical response...
April 5, 2017: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/28356978/reproducibility-of-the-egfr-immunohistochemistry-scores-for-tumor-samples-from-patients-with-advanced-non-small-cell-lung-cancer
#15
Alejandro Avilés-Salas, Saé Muñiz-Hernández, Héctor Aquiles Maldonado-Martínez, José G Chanona-Vilchis, Laura-Alejandra Ramírez-Tirado, Norma HernáNdez-Pedro, Rita Dorantes-Heredia, José Manuel RuíZ-Morales, Daniel Motola-Kuba, Oscar Arrieta
Epidermal growth factor receptor (EGFR) is overexpressed in >60% of non-small cell lung cancer (NSCLC) cases. In combination with radiotherapy or chemotherapy, first-line treatments with antibodies against EGFR, including cetuximab and necitumumab, have demonstrated benefits by increasing overall survival (OS), particularly in patients who overexpress EGFR. The present study evaluated the interobserver agreement among three senior pathologists, who were blinded to the clinical outcomes and assessed tumor samples from 85 patients with NSCLC using the H-score method...
February 2017: Oncology Letters
https://www.readbyqxmd.com/read/28325607/japanese-clinical-practice-guideline-for-head-and-neck-cancer
#16
REVIEW
Ken-Ichi Nibu, Ryuichi Hayashi, Takahiro Asakage, Hiroya Ojiri, Yoshihiro Kimata, Takeshi Kodaira, Toshitaka Nagao, Torahiko Nakashima, Takashi Fujii, Hirofumi Fujii, Akihiro Homma, Kazuto Matsuura, Nobuya Monden, Takeshi Beppu, Nobuhiro Hanai, Tadaaki Kirita, Yuzuru Kamei, Naoki Otsuki, Naomi Kiyota, Sadamoto Zenda, Ken Omura, Koichi Omori, Tetsuo Akimoto, Kazuyoshi Kawabata, Seiji Kishimoto, Hiroya Kitano, Iwai Tohnai, Takashi Nakatsuka
OBJECTIVE: The first revision of "Japanese Clinical Practice Guideline for Head and Neck Cancer" was made in 2013 by the clinical practice guideline committee of Japan Society for Head and Neck Cancer, in response to the revision of the TNM classification. METHODS: 34 CQs (Clinical Questions) were newly adopted to describe the diagnosis and treatment methods currently considered most appropriate, and offered recommendation grade made by the consensus of the committee...
August 2017: Auris, Nasus, Larynx
https://www.readbyqxmd.com/read/28259294/understanding-c-met-signalling-in-squamous-cell-carcinoma-of-the-head-neck
#17
REVIEW
P Szturz, E Raymond, C Abitbol, S Albert, A de Gramont, S Faivre
c-MET is a membrane spanning receptor tyrosine kinase for hepatocyte growth factor (HGF) also termed scatter factor. Transmitting signals from mesenchymal to epithelial cells, the HGF/c-MET axis mediates a range of biological processes that stimulate proliferation, motility, invasiveness, morphogenesis, apoptosis, and angiogenesis. Aberrant c-MET signal transduction favours tumorigenesis with the acquisition of invasive and metastatic phenotypes. Biological functions of c-MET may strongly vary according to microenvironmental changes, which occur at different stages of tumorigenesis and include also HGF/c-MET activation in stromal cells...
March 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28247918/management-of-radiodermatitis-associated-with-cetuximab-in-squamous-cell-carcinomas-of-the-head-and-neck
#18
REVIEW
Michelle Villavicencio, Martin Granados-García, Esther Vilajosana, Judith Domínguez-Cherit
The objective of this review is to report to the medical community the most recent knowledge on prevention and management of dermatitis with the use of cetuximab simultaneously with radiotherapy in the treatment of squamous cell carcinomas of the head and neck. A review was conducted in PubMed of English language publications between 2010 and 2015. The search employed the terms 'skin toxicity', 'radiodermatitis', 'cetuximab', 'radiotherapy', and 'head and neck cancer'. Data related to the classification and management of dermatitis, associated with cetuximab with concomitant radiotherapy (n = 22), were critically reviewed...
March 1, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28237868/a-pet-based-nomogram-for-oropharyngeal-cancers
#19
J Castelli, A Depeursinge, V Ndoh, J O Prior, M Ozsahin, A Devillers, H Bouchaab, E Chajon, R de Crevoisier, N Scher, F Jegoux, B Laguerre, B De Bari, J Bourhis
PURPOSE: In the context of locally advanced oropharyngeal cancer (LAOC) treated with definitive radiotherapy (RT) (combined with chemotherapy or cetuximab), the aims of this study were: (1) to identify PET-FDG parameters correlated with overall survival (OS) from a first cohort of patients; then (2) to compute a prognostic score; and (3) finally to validate this scoring system in a second independent cohort of patients. MATERIALS AND METHODS: A total of 76 consecutive patients (training cohort from Rennes) treated with chemoradiotherapy or RT with cetuximab for LAOC were used to build a predictive model of locoregional control (LRC) and OS based on PET-FDG parameters...
April 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28237712/the-efficiency-and-adverse-events-of-radiotherapy-with-cetuximab-for-japanese-head-and-neck-cancer-patients
#20
Kazuhiro Hirasawa, Isaku Okamoto, Ray Motohashi, Hiroki Sato, Soichiro Takase, Ayumi Agata, Atsuo Takeda, Kiyoaki Tsukahara
OBJECTIVES: Radiotherapy with cisplatin (Chemoradiotherapy, CRT) has long been one of the standard treatments for head and neck squamous cell cancer (HNSCC). Approval of cetuximab for the treatment of HNSCC has made radiotherapy with cetuximab (Bioradiotherapy, BRT) a new treatment option for HNSCC. Reports of BRT in the Japanese written in English up to now is only the phase II study, though it includes only 22 patients. Also on the nature of the clinical Phase II trial, sampling bias of cases may exist...
February 22, 2017: Auris, Nasus, Larynx
keyword
keyword
104263
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"